Developer docs
API playgroundTry for free, no card

Search company profiles

Gynesonics

Full company profile

uuid0000bcb

Namestring
Gynesonics
Legal namestring
Gynesonics, Inc.
Websiteurl
gynesonics.com
Company typeenum
Private
Founded yearint
2005
Descriptiontext

Gynesonics is a medical device company founded in 2005 and headquartered in Redwood City, California, that developed the Sonata System, an incisionless transcervical radiofrequency ablation platform for the treatment of symptomatic uterine fibroids and heavy menstrual bleeding. The system uses intrauterine ultrasound guidance to target and ablate fibroids without surgical incision, positioning it as a minimally invasive alternative to traditional hysterectomy or myomectomy procedures. The company operated as a single-product, vertically focused medtech firm, selling its hardware to hospitals, outpatient surgery centers, and gynecology clinics through an enterprise field sales motion, with marketing conducted at women's health and gynecological medical conferences.

The company's revenue model was based on medical device hardware sales of the Sonata System and related consumables used in radiofrequency fibroid ablation procedures, with pricing conducted on a quote basis through healthcare procurement channels. Gynesonics maintained a European commercial presence, evidenced by a dedicated VP of European Sales & Marketing, and pursued distribution through hospital and health system procurement processes globally. Over its independent lifetime, the company raised approximately $400 million+ across 15+ funding rounds from investors including Abingworth, Bain Capital Life Sciences, Endeavour Vision, HBM Partners, InterWest Partners, Hercules Capital, Advanced Technology Ventures, Amzak Health Investors, Kaiser Permanente Ventures, MVM Life Science Partners, and Runway Growth Capital.

In October 2024, Gynesonics was acquired by Hologic, Inc. for approximately $350 million, integrating the Sonata System into Hologic's GYN Surgical business and broader women's health portfolio. The acquisition expanded Hologic's fibroid treatment offerings within a GYN Surgical franchise that has delivered 7.6% CAGR over the past decade. Post-acquisition, Gynesonics ceased to operate as an independent entity and now functions as a subsidiary or product line under Hologic's corporate umbrella, leveraging Hologic's established global distribution network spanning 36 countries.

Short descriptiontext

Gynesonics developed the Sonata System, an incisionless transcervical radiofrequency ablation device for treating uterine fibroids and heavy menstrual bleeding. The Redwood City, California medical device company was acquired by Hologic in October 2024 for approximately $350 million.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersRedwood City, United States
HQ citystring
Redwood City
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
medical device manufacturing, women's health technology, minimally invasive surgery, radiofrequency ablation devices, uterine fibroid treatment
Industry3 codes
PRIMARYHLAKAJAF
Minimally Invasive Gynecologic Surgery (Laparoscopy/Hysteroscopy)
SECONDARYHLAHADAH
Intraoperative Imaging & Guidance (C-arms, O-arm, IOUS, fluorescence)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Surgical Instruments, Endoscopy & OR Equipment
SECONDARYHLAHABAD
Ultrasound & Echography Systems
Healthcare & Life Sciences/Medical Devices & Diagnostics/Medical Imaging & Radiology Equipment
NAICS code2 codes
  • Surgical and Medical Instrument Manufacturing339112
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code2 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
Women's Health Medical Devices
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Medical Device Sales
TypeHardware Sales
Description

Sale of the Sonata System and related consumables for radiofrequency fibroid treatment procedures in hospitals and outpatient settings

openpr.com
Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1Sonata System
Description

Incisionless radiofrequency ablation device for the treatment of uterine fibroids and heavy menstrual bleeding

precedenceresearch.com
Core offering1 text field

Gynesonics develops and sells the Sonata System, an incisionless, transcervical radiofrequency ablation device used to treat symptomatic uterine fibroids and associated heavy menstrual bleeding. The system combines intrauterine ultrasound guidance with RF ablation to target fibroids without surgical incisions, enabling an outpatient, uterus-preserving alternative to hysterectomy or myomectomy for hospitals, outpatient surgery centers, and gynecologists.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Gynesonics is a medical device company that developed the Sonata System, an incisionless radiofrequency ablation platform for treating uterine fibroids and associated heavy menstrual bleeding. The company's flagship product offers a minimally invasive alternative to traditional hysterectomy or myomectomy procedures. Gynesonics was acquired by Hologic in October 2024 for approximately $350 million, expanding Hologic's women's health portfolio with the Sonata System.

Product and service1 record
1Sonata System
Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2024-10-01
Description

Hologic acquired Gynesonics in October 2024 for approximately $350 million to incorporate the Sonata System into Hologic's women's health portfolio. The acquisition expands Hologic's fibroid treatment offerings as part of their GYN Surgical business, which has delivered 7.6% CAGR over the past decade.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Market position
Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds17 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors14 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Gynesonics

Women's Health Medical Devicesgynesonics.com

Gynesonics developed the Sonata System, an incisionless transcervical radiofrequency ablation device for treating uterine fibroids and heavy menstrual bleeding. The Redwood City, California medical device company was acquired by Hologic in October 2024 for approximately $350 million.

What Gynesonics does

Gynesonics is a medical device company founded in 2005 and headquartered in Redwood City, California, that developed the Sonata System, an incisionless transcervical radiofrequency ablation platform for the treatment of symptomatic uterine fibroids and heavy menstrual bleeding. The system uses intrauterine ultrasound guidance to target and ablate fibroids without surgical incision, positioning it as a minimally invasive alternative to traditional hysterectomy or myomectomy procedures. The company operated as a single-product, vertically focused medtech firm, selling its hardware to hospitals, outpatient surgery centers, and gynecology clinics through an enterprise field sales motion, with marketing conducted at women's health and gynecological medical conferences.

The company's revenue model was based on medical device hardware sales of the Sonata System and related consumables used in radiofrequency fibroid ablation procedures, with pricing conducted on a quote basis through healthcare procurement channels. Gynesonics maintained a European commercial presence, evidenced by a dedicated VP of European Sales & Marketing, and pursued distribution through hospital and health system procurement processes globally. Over its independent lifetime, the company raised approximately $400 million+ across 15+ funding rounds from investors including Abingworth, Bain Capital Life Sciences, Endeavour Vision, HBM Partners, InterWest Partners, Hercules Capital, Advanced Technology Ventures, Amzak Health Investors, Kaiser Permanente Ventures, MVM Life Science Partners, and Runway Growth Capital.

In October 2024, Gynesonics was acquired by Hologic, Inc. for approximately $350 million, integrating the Sonata System into Hologic's GYN Surgical business and broader women's health portfolio. The acquisition expanded Hologic's fibroid treatment offerings within a GYN Surgical franchise that has delivered 7.6% CAGR over the past decade. Post-acquisition, Gynesonics ceased to operate as an independent entity and now functions as a subsidiary or product line under Hologic's corporate umbrella, leveraging Hologic's established global distribution network spanning 36 countries.

Gynesonics firmographics

Firmographics
Name
Gynesonics
Legal name
Gynesonics, Inc.
Website
https://gynesonics.com
Company type
Private
Founded year
2005
Operating status
Acquired
Headcount range
51–100 employees
Short description
Gynesonics developed the Sonata System, an incisionless transcervical radiofrequency ablation device for treating uterine fibroids and heavy menstrual bleeding. The Redwood City, California medical device company was acquired by Hologic in October 2024 for approximately $350 million.
Ownership category
akta.pro rank

Gynesonics industry classification

Industry
Product category
Women's Health Medical Devices
NAICS
Surgical and Medical Instrument Manufacturing (339112), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)
akta.pro industry
PRIMARYHLAKAJAF
Minimally Invasive Gynecologic Surgery (Laparoscopy/Hysteroscopy)
SECONDARYHLAHADAH
Intraoperative Imaging & Guidance (C-arms, O-arm, IOUS, fluorescence)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Surgical Instruments, Endoscopy & OR Equipment
SECONDARYHLAHABAD
Ultrasound & Echography Systems
Healthcare & Life Sciences/Medical Devices & Diagnostics/Medical Imaging & Radiology Equipment

Keywords

  • Medical device manufacturing
  • Women's health technology
  • Minimally invasive surgery
  • Radiofrequency ablation devices
  • Uterine fibroid treatment

Where Gynesonics is headquartered

Location

Headquarters

HQ city
Redwood City
HQ country
United States
HQ region
North America

Markets served

Gynesonics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

  1. Medical Device Sales: Sale of the Sonata System and related consumables for radiofrequency fibroid treatment procedures in hospitals and outpatient settings

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Gynesonics product offering

Product offering

Core offering

Gynesonics develops and sells the Sonata System, an incisionless, transcervical radiofrequency ablation device used to treat symptomatic uterine fibroids and associated heavy menstrual bleeding. The system combines intrauterine ultrasound guidance with RF ablation to target fibroids without surgical incisions, enabling an outpatient, uterus-preserving alternative to hysterectomy or myomectomy for hospitals, outpatient surgery centers, and gynecologists.

Product overview

Gynesonics is a medical device company that developed the Sonata System, an incisionless radiofrequency ablation platform for treating uterine fibroids and associated heavy menstrual bleeding. The company's flagship product offers a minimally invasive alternative to traditional hysterectomy or myomectomy procedures. Gynesonics was acquired by Hologic in October 2024 for approximately $350 million, expanding Hologic's women's health portfolio with the Sonata System.

Differentiator

Problem solved

Functional benefit

Brands

  • Sonata System: Incisionless radiofrequency ablation device for the treatment of uterine fibroids and heavy menstrual bleeding

Products and services

  • Sonata System

Companies that use Gynesonics

Customer profile

Segments1 record

Ideal customer profiles1 record

Gynesonics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Gynesonics partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • HologicflagshipStrategic or Co-development Partner · 1 October 2024Hologic acquired Gynesonics in October 2024 for approximately $350 million to incorporate the Sonata System into Hologic's women's health portfolio. The acquisition expands Hologic's fibroid treatment offerings as part of their GYN Surgical business, which has delivered 7.6% CAGR over the past decade.

Scale indicators2 records

Recent moves6 records

Expansion highlights4 records

Gynesonics competitors and assessment

Company assessment

Market position

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Gynesonics social profiles

Digital presence

Gynesonics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Gynesonics leadership team

Management profile

Number of profiles

Profiles7 records

Gynesonics funding detail

Funding detail

Funding overview

Funding rounds17 records

Investors14 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Gynesonics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Gynesonics

What does Gynesonics do?

Gynesonics develops and sells the Sonata System, an incisionless, transcervical radiofrequency ablation device used to treat symptomatic uterine fibroids and associated heavy menstrual bleeding. The system combines intrauterine ultrasound guidance with RF ablation to target fibroids without surgical incisions, enabling an outpatient, uterus-preserving alternative to hysterectomy or myomectomy for hospitals, outpatient surgery centers, and gynecologists.

Is Gynesonics a public or private company?

Gynesonics is a private company. It is classified as corporate owned and is currently acquired.

When was Gynesonics founded?

Gynesonics was founded in 2005. It employs 51 to 100 people.

Where is Gynesonics based?

Gynesonics is headquartered in Redwood City, United States, in the North America region.

How does Gynesonics make money?

One revenue line is on record: medical Device Sales.

Does Gynesonics have an API?

No public API is recorded for Gynesonics.

What industry is Gynesonics in?

Gynesonics's product category is Women's Health Medical Devices. Its primary akta.pro industry code is HLAKAJAF, Minimally Invasive Gynecologic Surgery (Laparoscopy/Hysteroscopy), with a secondary code of HLAHADAH, Intraoperative Imaging & Guidance (C-arms, O-arm, IOUS, fluorescence). Its NAICS code is 339112 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
openPR.comTop Players and Market Competition in the Women's Health Diagnostics SectorThe women's health diagnostics market is projected to grow to $59.02 billion by 2030 at a 10.0% compound annual growth rate, driven by advances in AI analytics, personalized diagnostics, and home-based testing solutions. In October 2024, Hologic acquired Gynesonics to expand its portfolio of minimally invasive women's health treatments targeting uterine fibroids and heavy menstrual bleeding. Samsung's digital radiography and ultrasound division launched the HERA W10 Elite women's health ultrasound system in February 2023, featuring AI-powered diagnostic tools for obstetrics and gynecology.EIN PresswireHysteroscopy Instruments Market to Reach USD 3.45 Billion by 2032 at 7.2% CAGR, Reveals Maximize Market ResearchThe global hysteroscopy instruments market is projected to grow from USD 1.98 billion in 2024 to USD 3.45 billion by 2032 at a 7.2% CAGR. Growth is driven by AI imaging, disposable scopes, and rising gynecological disorders, with North America holding ~44% share and Asia-Pacific as the fastest-growing region.openPR.comTrends in Growth, Segment Analysis, and Competitive Strategies Influencing the Menorrhalgia MarketThe menorrhalgia market is projected to reach $29.36 billion by 2030, growing at a compound annual growth rate of 6.0%, driven by increasing demand for fertility-preserving therapies, improved access to gynecological care, and rising acceptance of non-hormonal treatments. In January 2025, Hologic Inc. acquired Gynesonics Inc. to strengthen its portfolio of minimally invasive solutions for uterine fibroids and heavy menstrual bleeding. The market analysis identifies numerous pharmaceutical and medical device companies operating in this space, including Bayer, Pfizer, Novartis, and Boston Scientific.openPR.comEmerging Growth Patterns Driving Expansion in the Women's Health Devices MarketThe women's health devices market is projected to reach $77.08 billion by 2030, growing at a compound annual growth rate of 11.7%, driven by femtech innovation, personalized healthcare, and wearable technologies. In October 2024, Hologic Inc. acquired Gynesonics Inc. for approximately $350 million to enhance its portfolio in minimally invasive gynecological treatments, incorporating Gynesonics' transcervical fibroid-treatment system. Additionally, in January 2023, Movano Health launched the Evie smart ring for women, an FDA-compliant wearable device tracking health metrics including heart rate, blood oxygen, menstrual cycles, and sleep patterns.Precedence ResearchGynecological Devices Market Size to Hit USD 24.75 Billion by 2035The global gynecological devices market is valued at USD 11.38 billion in 2025 and is projected to reach USD 24.75 billion by 2035, growing at a CAGR of 8.08%, driven by rising gynecological disease prevalence and technological advancements in minimally invasive procedures. In May 2025, the FDA approved the Teal Wand, the first-ever at-home cervical cancer screening kit, enabling self-collection for individuals aged 25-65 with 96% clinical accuracy. Additionally, Hologic announced a $350 million acquisition of Gynesonics in October 2024 to incorporate the Sonata System, an incisionless radiofrequency fibroid treatment, into its women's health portfolio.Precedence ResearchWomen’s Health Devices Market Size to Hit USD 82.03 Bn by 2034According to market research by Precedence Research, the global women's health devices market is valued at approximately USD 39.27 billion in 2025 and is projected to reach USD 82.03 billion by 2034, growing at a CAGR of 8.51%, driven by rising awareness of women's health concerns, increased healthcare expenditure, and adoption of advanced diagnostics. North America dominated the market in 2024 with a 33.3% share, while Asia Pacific is identified as the fastest-growing region. Notable recent developments include GE HealthCare receiving FDA 510(k) clearance for its Voluson Expert Series ultrasound systems in January 2025, and Hologic's acquisition of Gynesonics for approximately $350 million in October 2024.ForbesWomen’s Health Innovation Delivers For Investors And PatientsFemHealth Ventures, a women's health fund founded in 2021, reported a 0.95x DPI as of January 2025, placing it in the top decile of its vintage. Its portfolio company Gynesonics was acquired by Hologic for $350 million in late 2024. The firm argues women's health is a $1 trillion opportunity.ForbesHow Venture Capital Investment In Women’s Health Changed In 2024U.S.-based women's health companies raised $1.19 billion across 111 deals in 2024, a modest 4.3% increase from 2023's $1.14 billion but below the 2021 record of $1.31 billion, with average deal size reaching a new high of $10.71 million. However, women's health's share of total healthcare venture capital funding dropped sharply to 2.3% in 2024 from 2023's record-high 4.1%, representing a 43% year-over-year decline despite women comprising half the population and being majority healthcare consumers. The year also saw a reversal of 2023's progress on gender equity, with female founders raising an average of $9.1 million compared to male founders' $21.6 million, while notable acquisitions included IVI RMA America's $535 million purchase of Eugin Group's North American operations and Hologic's $350 million acquisition of Gynesonics.Radiology BusinessHologic finalizes $350M acquisition of ultrasound imaging device developerHologic Inc. has finalized the $350 million acquisition of Gynesonics, a developer of ultrasound imaging devices for treating fibroids. This transaction marks Hologic's latest strategic purchase, following several smaller acquisitions since 2020 aimed at expanding its product portfolio and growth trajectory.Pulse 2.0Hologic: $350 Million Acquisition Of Gynesonics CompletedHologic completed its acquisition of Gynesonics for about $350 million. The deal adds the Sonata System, a minimally invasive device for diagnosing and treating uterine fibroids, to Hologic's women's health portfolio. The acquisition aims to expand access to the technology for surgeons.